Home›Trial›NCT06982521
🔬NCT06982521Phase 3RECRUITING

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

Study Summary

This is a global, multicenter, open-label, randomized Phase 3 study comparing the efficacy and safety of RLY-2608 + fulvestrant to capivasertib + fulvestrant for the treatment of patients with HR+/HER2- ABC with PIK3CA mutation following recurrence or progression on or after treatment with a CDK4/6 inhibitor.

Conditions
PIK3CA MutationHER2- Negative Breast CancerHormone Receptor Positive TumorBreast CancerMetastatic Breast CancerAdvanced Breast Cancer
Interventions / Drugs
RLY-2608CapivasertibFulvestrant
View on ClinicalTrials.gov ↗
Sponsor
RLAY
Relay Therapeutics
Precision Oncology
D37/100
Study Details
Enrollment540 participants
Primary Completion—
Lead SponsorRelay Therapeutics, Inc.
Data Retrieved2026-04-11 04:26:00.986203+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.